BIIB vs GILD
BIIB and GILD side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BIIBBIOGEN INC. | GILDGILEAD SCIENCES, INC. |
|---|---|---|
| Market cap | $37.49B | $212.04B |
| P/E (TTM) | 109.8 | 25.2 |
| P/B | 2.53 | 16.26 |
| P/S | 3.8x | 7.2x |
| Dividend yield | — | 1.89% |
| Revenue | $10.30B(TTM) | $30.99B(TTM) |
| Revenue growth (YoY) | 2.2% | 2.4% |
| Net income | $347.60M(TTM) | -$3.86B(TTM) |
| Earnings growth (YoY) | -20.8% | 1672.9% |
| EPS, diluted | $2.31(TTM) | $-3.13(TTM) |
| EBIT margin | 28.7% | 34.0% |
| ROE | 8.7% | 65.3% |
| ROIC | 12.3% | 25.7% |
| Piotroski F | 3/9 | — |
| 1y total return | +69.6% | +47.1% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: BIIB vs GILD
| 지표 | BIIB | GILD |
|---|---|---|
| 최종 가치 | $10.6K | $29.7K |
| 총수익률 | +6.2% | +197.3% |
| CAGR | +0.6% | +11.1% |
| 변동성 | 41.1% | 25.6% |
| 샤프 | 0.11 | 0.38 |
| 소르티노 | 0.18 | 0.56 |
| 최대 낙폭 | -72.7% | -30.5% |
공통 거래일 2600일 기준, 2016-06-29 → 2026-10-30 · 무위험수익률 4.16% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)